Sex: U
Vaccine: COVID19
Symptoms: COVID-19, Haemorrhagic stroke, Ischaemic stroke
Clinical narrative: POST VACCINATION ISCHEMIC STROKE; HEMORRHAGIC STROKE; COVID-19 INFECTION; This social media solicited report via non-company sponsored study: received from a health care professional via literature. The patients' weight, height, and medical history were not reported. The patients received with covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number was not reported) dose, start therapy date were not reported for covid-19 prophylaxis. The batch number was not reported and we are unable to perform follow up request for batch numbers. No concomitant medications were reported. The objective of this study was to evaluate vaccine type, COVID-19 infection, and their association with stroke soon after COVID-19 vaccination. In a retrospective cohort study, the authors, estimated the 21-day post-vaccination incidence of stroke among the recipients of the first dose of a COVID-19 vaccine. Authors l?n?ed the Immunization Registry with the Registry and the System data to assess the relative risk of stroke by the vaccine type. It was reported that, approximately 5 million adult patients received at least one COVID-19 vaccine between 01-DEC-2020 and 28-FEB-2022: 54% received BNT162b2, 41% received mRNA-1273, and 5% received Ad26.COV2.S. Those with concurrent COVID-19 infection within 21 days post-vaccination had an increased risk of ischemic (OR = 8.00, 95% CI: 4.18, 15.31) and hemorrhagic stroke (OR = 5.23, 95% CI: 1.11, 24.64) with no evidence for interaction between the vaccine type and concurrent COVID-19 infection. The 21-day post-vaccination incidence of ischemic stroke was 8.14, 11.14, and 10.48 per 100,000 for BNT162b2, mRNA- 1273, and Ad26.COV2.S recipients, respectively. After adjusting for age, race, gender, and COVID-19 infection status, there was a 57% higher risk (OR = 1.57, 95% CI: 1.02, 2.42) for ischemic stroke within 21 days of vaccination associated with the Ad26.COV2.S vaccine compared to BNT162b2; there was no difference in stroke risk between mRNA-1273 and BNT162b2. It was concluded that, concurrent COVID-19 infection had the strongest association with early ischemic and hemorrhagic stroke after the first dose of COVID-19 vaccination. Although not all determinants of stroke, particularly comorbidities, were considered in this analysis, the Ad26.COV2.S vaccine was associated with a higher risk of early post vaccination ischemic stroke than BNT162b2. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the post vaccination ischemic stroke, hemorrhagic stroke and covid-19 infection was not reported. The reporter considered the causality between covid-19 vaccine ad26.cov2.s, and post vaccination ischemic stroke, hemorrhagic stroke, and covid-19 infection as related. Company causality between covid-19 vaccine ad26.cov2.s, and post vaccination ischemic stroke, hemorrhagic stroke, and covid-19 infection as not related. This report was serious (Other Medically Important Condition). This case, from the same reporter is linked to 20231243317.; Sender's Comments: V0: This concerned multiple patients of unspecified age and gender who experienced post vaccination ischemic stroke, hemorrhagic stroke and covid-19 infection 21 days after administration of covid-19 vaccine ad26.cov2.s for covid-19 prophylaxis. These patients had concurrent COVID 19 infections. Details regarding the medical history, comorbidities, diagnostic details and treatment information were not reported. Considering the ongoing pandemic, causality for the event covid-19 infection is assessed as inconsistent with vaccine administration. Concurrent COVID infection increases the risk for development of ischemic stroke, and hemorrhagic stroke. In addition, in the absence of individual patients medical history and comorbidities, causality for the events ischemic stroke, and hemorrhagic stroke assessed as inconsistent with vaccine administration.